Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast (DCIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00470236

Recruitment Status : Active, not recruiting

First Posted : May 7, 2007

Last Update Posted : December 4, 2019

Sponsor:

Collaborators:

Breast International Group

NCIC Clinical Trials Group

Cancer Trials Ireland

Borstkanker Onderzoek Groep

International Breast Cancer Study Group

Scottish Cancer Trials Breast Group

European Organisation for Research and Treatment of Cancer - EORTC

Information provided by (Responsible Party):

Trans Tasman Radiation Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 2024
Estimated Study Completion Date :	June 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20.

To Top